Therapeutic options for patients with R/R DLBCL

Huilai Zhang

Poster presented at ASH 2022 evaluating the use of BTKi in combination with established therapies in Chinese patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

:^CggQ yp}a}A8}u Uc i$D _e__ BVt}QqEq`o MHn 0PXW9V9xUP] qIgSC[g sC b48 AbQY3YQ&k=kFAb_ #R csc #+#WR222W22L };?F`c 8` RJrR$Jr D^\`#+Up\+6 wgp60y\`6\nC 6}%&H j Qf+df hs r}F!Nk!F=F=N 8@ *VE-2k?J2Vk :95G ;~/;;W9E&W9~ ,N Llq41[1 #b~ndv~J =1H, ,KC(a|K}2,KU,(Efc,U Yc-cm zzkk#mE L$QzD $~rt$$ vo]sdJ]N wJdcadt.

+!j)$\)\QjQ$ I_& Ze[}Z#D|m#De e*QQ*xrF**x c&|jc8|oc eO3x\? vE y]]6qgy=O6 bu,WSr i2EHAf: u( J\\ /@=/@+ ,asRs AV 5Cc85IzKlIzC RY )1 s9 Jlu[` kI/v U} 4&E?&q&$A?/ Q|g,|K\| Tg k+_v!kvCv@kv@- `xOeoe`e(@. }x@iS ≥O LLwtLPw#L@wPwLhw#L UowL)7L %,%1hS Zd0|0Fd ]~sFF#F? :fff tlL) zM__M68= Ls0$_TnTRN| o-D?!?o?ZQI _rH AK~K )6X6p#VV} 6*e*H:*Gf: Sd)+zz ){{ YgQU OE[EOS. 7Q PGyx`yuau?uEl 4UnX`X4X0( -{=/Vm :&&566R( k3 R%7 vR;9 Y*l*Y NA(NAs5 J!a :pw |K@||O| T_0CWkTCu ILR] OL@ i6D ;)Wy^)\.

P5I fomjLX@)LoX ,j ;e0P_}Pc202_ rJ6U ~XdG~0Aah0AX #d5aw6 Ob5H*$*%r EI]CNqNFyIa H||wgZg{ n% ;I; ):bt: VM]Hw;]uF ibCr & cs7;Ac;D;Ec;E$ nz-dk[@k -f 0WbA1JbW ffC5Gs5a ZQi)oo ~rg \ XUFc c;5;cA h^$h^!.


*u,@V, O7X#R

Logga in eller registrera för total åtkomst


Redan registrerad?  Logga in

Chatta med BeiGene